Loading...
Research update on the anticancer effects of buparlisib
Buparlisib is a highly efficient and selective PI3K inhibitor and a member of the 2,6-dimorpholinopyrimidine-derived family of compounds. It selectively inhibits four isomers of PI3K, PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, by competitively binding the lipid kinase domain on adenosine 5′-triphosphate (ATP),...
Saved in:
| Published in: | Oncol Lett |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
D.A. Spandidos
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7885152/ https://ncbi.nlm.nih.gov/pubmed/33717263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2021.12527 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|